Inotek Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ITEK)

$2.39 -0.05 (-2.05 %)
(As of 12/18/2017 01:42 AM ET)
Previous Close$2.44
Today's Range$2.37 - $2.47
52-Week Range$0.85 - $7.40
Volume128,200 shs
Average Volume1.08 million shs
Market Capitalization$65.06 million
P/E RatioN/A
Dividend YieldN/A
Beta3.15

About Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals logoInotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Receive ITEK News and Ratings via Email

Sign-up to receive the latest news and ratings for ITEK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ITEK
CUSIPN/A
Phone781-676-2100

Debt

Debt-to-Equity Ratio0.97%
Current Ratio27.63%
Quick Ratio27.63%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.72 per share
Price / Book0.88

Profitability

Trailing EPS($1.53)
Net Income$-42,850,000.00
Net MarginsN/A
Return on Equity-61.38%
Return on Assets-32.46%

Miscellaneous

Employees24
Outstanding Shares27,220,000

Inotek Pharmaceuticals (NASDAQ:ITEK) Frequently Asked Questions

What is Inotek Pharmaceuticals' stock symbol?

Inotek Pharmaceuticals trades on the NASDAQ under the ticker symbol "ITEK."

How were Inotek Pharmaceuticals' earnings last quarter?

Inotek Pharmaceuticals Corp (NASDAQ:ITEK) issued its earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.23. View Inotek Pharmaceuticals' Earnings History.

When will Inotek Pharmaceuticals make its next earnings announcement?

Inotek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, December, 20th 2017. View Earnings Estimates for Inotek Pharmaceuticals.

Where is Inotek Pharmaceuticals' stock going? Where will Inotek Pharmaceuticals' stock price be in 2017?

3 Wall Street analysts have issued 1-year price objectives for Inotek Pharmaceuticals' shares. Their predictions range from $2.00 to $3.00. On average, they anticipate Inotek Pharmaceuticals' stock price to reach $2.67 in the next year. View Analyst Ratings for Inotek Pharmaceuticals.

What are Wall Street analysts saying about Inotek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inotek Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inotek Pharmaceuticals Corporation is a biopharmaceutical company. The company is focused on the discovery, development and commercialization of novel therapies to treat glaucoma and diseases of the eye. Inotek Pharmaceuticals Corporation is headquartered in Lexington, Massachusetts. " (9/12/2017)
  • 2. HC Wainwright analysts commented, "Phase 2 FDC data release narrowed to July. With the timing of Inotek’s Phase 2 fixed-dose combination (FDC) trial readout nearing, the company issued a release refining that window from mid-2017 to July, as enrollment for the study has now been completed. The market is not expecting a lot after the MATrX-1 study failed to beat placebo in January, but there is still a glimmer of hope for a positive outcome. Given the company’s enterprise value of negative $27M, we see a much stronger case for the upside (potential confirmation of efficacy with the more valuable, in our view, FDC product) versus limited downside." (4/12/2017)

Who are some of Inotek Pharmaceuticals' key competitors?

Who are Inotek Pharmaceuticals' key executives?

Inotek Pharmaceuticals' management team includes the folowing people:

  • J. Martin Carroll, Independent Chairman of the Board (Age 68)
  • David P. Southwell, President, Chief Executive Officer, Director (Age 56)
  • Dale Ritter, Vice President—Finance, Principal Financial and Accounting Officer, Treasurer, Secretary (Age 66)
  • Rudolf A. Baumgartner M.D., Executive Vice President, Chief Medical Officer (Age 57)
  • Timothy Joseph Barberich, Independent Director (Age 69)
  • Carsten Boess, Independent Director (Age 50)
  • Paul G. Howes, Independent Director (Age 62)
  • Patrick Machado J.D., Independent Director (Age 53)
  • Gary M. Phillips M.D., Independent Director (Age 51)

When did Inotek Pharmaceuticals IPO?

(ITEK) raised $40 million in an initial public offering (IPO) on Wednesday, February 18th 2015. The company issued 6,700,000 shares at $6.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Nomura were co-managers.

Who owns Inotek Pharmaceuticals stock?

Inotek Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (6.89%), Jennison Associates LLC (5.72%), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.55%), BML INVESTMENT PARTNERS, L.P. (4.90%), Pura Vida Investments LLC (4.21%) and Point72 Asset Management L.P. (2.33%). Company insiders that own Inotek Pharmaceuticals stock include David P Southwell and J Martin Carroll. View Institutional Ownership Trends for Inotek Pharmaceuticals.

Who bought Inotek Pharmaceuticals stock? Who is buying Inotek Pharmaceuticals stock?

Inotek Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Pura Vida Investments LLC, Point72 Asset Management L.P., GSA Capital Partners LLP and Boothbay Fund Management LLC. Company insiders that have bought Inotek Pharmaceuticals stock in the last two years include David P Southwell and J Martin Carroll. View Insider Buying and Selling for Inotek Pharmaceuticals.

How do I buy Inotek Pharmaceuticals stock?

Shares of Inotek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inotek Pharmaceuticals' stock price today?

One share of Inotek Pharmaceuticals stock can currently be purchased for approximately $2.39.

How big of a company is Inotek Pharmaceuticals?

Inotek Pharmaceuticals has a market capitalization of $65.06 million. The biotechnology company earns $-42,850,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Inotek Pharmaceuticals employs 24 workers across the globe.

How can I contact Inotek Pharmaceuticals?

Inotek Pharmaceuticals' mailing address is 91 HARTWELL AVE 2ND FLOOR, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-676-2100 or via email at [email protected]


MarketBeat Community Rating for Inotek Pharmaceuticals (ITEK)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Inotek Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inotek Pharmaceuticals (NASDAQ:ITEK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.252.252.252.75
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$4.50$5.75
Price Target Upside: 373.68% upside373.68% upside373.68% upside248.48% upside

Inotek Pharmaceuticals (NASDAQ:ITEK) Consensus Price Target History

Price Target History for Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals (NASDAQ:ITEK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/12/2017Canaccord GenuityDowngradeBuy -> HoldMediumView Rating Details
7/11/2017HC WainwrightDowngradeBuy -> Neutral$2.00HighView Rating Details
1/3/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$3.00N/AView Rating Details
12/1/2016Roth CapitalInitiated CoverageBuy$10.00N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Inotek Pharmaceuticals (NASDAQ:ITEK) Earnings History and Estimates Chart

Earnings by Quarter for Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals (NASDAQ ITEK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/20/2017        
8/3/2017Q2 2017($0.47)($0.24)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.39)($0.40)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)($0.48)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.45)($0.41)ViewN/AView Earnings Details
8/10/2016Q2($0.40)($0.33)ViewN/AView Earnings Details
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.29)($0.26)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Inotek Pharmaceuticals (NASDAQ:ITEK) Earnings Estimates

2017 EPS Consensus Estimate: ($1.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.31)($0.31)($0.31)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Inotek Pharmaceuticals (NASDAQ:ITEK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Inotek Pharmaceuticals (NASDAQ ITEK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 37.07%
Insider Trades by Quarter for Inotek Pharmaceuticals (NASDAQ:ITEK)
Institutional Ownership by Quarter for Inotek Pharmaceuticals (NASDAQ:ITEK)

Inotek Pharmaceuticals (NASDAQ ITEK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2017David P. SouthwellInsiderBuy60,000$1.75$105,000.00View SEC Filing  
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.00View SEC Filing  
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inotek Pharmaceuticals (NASDAQ ITEK) News Headlines

Source:
DateHeadline
 Inotek Pharmaceuticals Corporation (ITEK) Given $20.00 Average Target Price by Brokerages Inotek Pharmaceuticals Corporation (ITEK) Given $20.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 2 at 11:30 PM
Inotek Pharmaceuticals: Upcoming Merger with Rocket and New PipelineInotek Pharmaceuticals: Upcoming Merger with Rocket and New Pipeline
finance.yahoo.com - November 3 at 10:51 AM
Comparing Inotek Pharmaceuticals Corporation (ITEK) & Its PeersComparing Inotek Pharmaceuticals Corporation (ITEK) & Its Peers
www.americanbankingnews.com - October 15 at 8:28 PM
Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage ... - Business Wire (press release)Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage ... - Business Wire (press release)
www.businesswire.com - October 13 at 7:53 PM
Pre-Market Most Active for Oct 13, 2017 : BAC, MON, ITEK, WFC, GSK, GE, T, MSFT, AAPL, CSCO, INTC, CMCSA - NasdaqPre-Market Most Active for Oct 13, 2017 : BAC, MON, ITEK, WFC, GSK, GE, T, MSFT, AAPL, CSCO, INTC, CMCSA - Nasdaq
www.nasdaq.com - October 13 at 7:53 PM
Wall Streets M&A Chatter From October 12: Kroger, Genesis Capital, Inotek Pharma-Rocket Pharma - BenzingaWall Street's M&A Chatter From October 12: Kroger, Genesis Capital, Inotek Pharma-Rocket Pharma - Benzinga
www.benzinga.com - October 13 at 7:53 PM
Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket PharmaceuticalsInotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals
finance.yahoo.com - October 13 at 3:24 AM
Is It The Right Time To Buy Inotek Pharmaceuticals Corporation (ITEK)?Is It The Right Time To Buy Inotek Pharmaceuticals Corporation (ITEK)?
finance.yahoo.com - September 22 at 1:41 PM
Todays Research Reports on Stocks to Watch: Inotek Pharmaceuticals and 22nd Century GroupToday's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and 22nd Century Group
finance.yahoo.com - September 15 at 2:19 AM
Inotek Pharma (ITEK) to Merge with Rocket Pharmaceuticals - StreetInsider.comInotek Pharma (ITEK) to Merge with Rocket Pharmaceuticals - StreetInsider.com
www.streetinsider.com - September 14 at 6:36 AM
Inotek Pharmaceuticals Corp (ITEK) versus Applied Genetic Technologies Corporation (AGTC) Financial AnalysisInotek Pharmaceuticals Corp (ITEK) versus Applied Genetic Technologies Corporation (AGTC) Financial Analysis
www.americanbankingnews.com - September 12 at 8:28 PM
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare DiseasesInotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
finance.yahoo.com - September 12 at 4:51 PM
Ignyta (RXDX) and Inotek Pharmaceuticals Corporation (ITEK) Head-To-Head SurveyIgnyta (RXDX) and Inotek Pharmaceuticals Corporation (ITEK) Head-To-Head Survey
www.americanbankingnews.com - September 4 at 2:12 AM
Vasuda Capital Management Seeks to Inspects Books and Records ... - StreetInsider.comVasuda Capital Management Seeks to Inspects Books and Records ... - StreetInsider.com
www.streetinsider.com - September 2 at 6:53 PM
Vasuda Capital Management Seeks to Inspects Books and Records of Inotek Pharmaceuticals (ITEK) Related to Potential SaleVasuda Capital Management Seeks to Inspects Books and Records of Inotek Pharmaceuticals (ITEK) Related to Potential Sale
www.streetinsider.com - August 31 at 8:02 PM
Inotek: No Products, No Pipeline, No Problem - Seeking AlphaInotek: No Products, No Pipeline, No Problem - Seeking Alpha
seekingalpha.com - August 20 at 7:14 PM
Inotek Pharmaceuticals Corporation (ITEK) Posts Quarterly  Earnings Results, Beats Expectations By $0.23 EPSInotek Pharmaceuticals Corporation (ITEK) Posts Quarterly Earnings Results, Beats Expectations By $0.23 EPS
www.americanbankingnews.com - August 4 at 5:46 PM
Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights - Business Wire (press release)Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights - Business Wire (press release)
www.businesswire.com - August 3 at 8:11 PM
Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational HighlightsInotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - August 3 at 8:11 PM
Inotek Pharmaceuticals reports 2Q lossInotek Pharmaceuticals reports 2Q loss
finance.yahoo.com - August 3 at 8:11 PM
After Another Clinical Failure, Is Inotek Dead Money? - Seeking AlphaAfter Another Clinical Failure, Is Inotek Dead Money? - Seeking Alpha
seekingalpha.com - July 18 at 4:54 PM
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by HC Wainwright to "Neutral"Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Downgraded by HC Wainwright to "Neutral"
www.americanbankingnews.com - July 11 at 7:50 AM
Todays Research Reports on Stocks to Watch: Ocular Therapeutix and Inotek PharmaceuticalsToday's Research Reports on Stocks to Watch: Ocular Therapeutix and Inotek Pharmaceuticals
finance.yahoo.com - July 10 at 7:59 PM
Inotek shares plunge after sole eye drug fails another trialInotek shares plunge after sole eye drug fails another trial
www.nasdaq.com - July 8 at 11:52 AM
Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate UpdateInotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update
finance.yahoo.com - July 8 at 11:52 AM
Inotek to consider strategic options after eye drug fails another studyInotek to consider strategic options after eye drug fails another study
finance.yahoo.com - July 8 at 11:52 AM
Lexington’s Inotek suggests it could explore sale after another trial flopLexington’s Inotek suggests it could explore sale after another trial flop
finance.yahoo.com - July 8 at 11:52 AM
Options Traders Expect Huge Moves in Inotek Pharmaceuticals (ITEK) StockOptions Traders Expect Huge Moves in Inotek Pharmaceuticals (ITEK) Stock
finance.yahoo.com - July 7 at 6:35 AM
Inotek Pharmaceuticals Is A Strong Buy Before Phase II Data In July - Seeking AlphaInotek Pharmaceuticals Is A Strong Buy Before Phase II Data In July - Seeking Alpha
seekingalpha.com - June 13 at 5:48 PM
Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and ... - Business Wire (press release)Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and ... - Business Wire (press release)
www.businesswire.com - May 10 at 1:14 PM
Inotek Pharmaceuticals reports 1Q lossInotek Pharmaceuticals reports 1Q loss
marketbeat.com - May 10 at 7:28 AM
Inotek Pharmaceuticals Could Be Getting A Second ChanceInotek Pharmaceuticals Could Be Getting A Second Chance
seekingalpha.com - March 21 at 5:58 PM
INOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements aINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
biz.yahoo.com - March 16 at 6:50 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds ... - GlobeNewswire (press release)DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 5:33 PM
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inotek Pharmaceuticals Corporation Investors and Encourages Investors to Contact the FirmGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Inotek Pharmaceuticals Corporation Investors and Encourages Investors to Contact the Firm
us.rd.yahoo.com - March 3 at 5:57 PM
ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017
feeds.benzinga.com - March 3 at 12:51 PM
Inotek Pharmaceuticals Announces Participation at Upcoming Investor ConferencesInotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
us.rd.yahoo.com - February 27 at 6:38 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEKSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017 – ITEK
feeds.benzinga.com - February 27 at 12:52 PM
Inotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society MeetingInotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society Meeting
www.streetinsider.com - February 25 at 12:20 AM
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the FirmIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Inotek Pharmaceuticals Corporation and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - February 25 at 12:20 AM
Inotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society Meeting - StreetInsider.comInotek Pharma (ITEK) Reports Poster Presentations at American Glaucoma Society Meeting - StreetInsider.com
www.streetinsider.com - February 24 at 7:17 PM
Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 ... - Business Wire (press release)Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 ... - Business Wire (press release)
www.businesswire.com - February 24 at 10:11 AM
IMPORTANT INOTEK INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP  announces that a securities class action lawsuit has been filed in the District of Massachusetts against Inotek Pharmaceuticals CorporationIMPORTANT INOTEK INVESTOR REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the District of Massachusetts against Inotek Pharmaceuticals Corporation
feeds.benzinga.com - February 23 at 6:03 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7 ...INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Class Action Lawsuit Against Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7 ...
www.businesswire.com - February 22 at 12:32 PM
ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff ...ITEK SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff ...
www.businesswire.com - February 18 at 5:24 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Inotek Pharmaceuticals Corporation (ITEK) and Lead Plaintiff Deadline - March 7, 2017
us.rd.yahoo.com - February 16 at 4:52 PM
Bragar Eagel & Squire, P.C. Reminds Investors...Bragar Eagel & Squire, P.C. Reminds Investors...
www.benzinga.com - February 15 at 5:30 AM
ITEK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek ... - PR Newswire (press release)ITEK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 12:27 AM
Bragar Eagel & Squire, PC Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inotek ... - Business Wire (press release)Bragar Eagel & Squire, PC Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inotek ... - Business Wire (press release)
www.businesswire.com - February 15 at 12:27 AM
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) and Encourages Investors with Losses ...Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inotek Pharmaceuticals Corporation (ITEK) and Encourages Investors with Losses ...
www.businesswire.com - February 14 at 7:25 PM

SEC Filings

Inotek Pharmaceuticals (NASDAQ:ITEK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inotek Pharmaceuticals (NASDAQ:ITEK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inotek Pharmaceuticals (NASDAQ ITEK) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.